106 related articles for article (PubMed ID: 3087373)
1. The interactions of mesna and dimesna with the sulfate exchange in human red blood cells.
Reuther H; Kohl M; Wildenauer DB
Arzneimittelforschung; 1986 Apr; 36(4):763-5. PubMed ID: 3087373
[TBL] [Abstract][Full Text] [Related]
2. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
Habs MR; Schmähl D
Cancer; 1983 Feb; 51(4):606-9. PubMed ID: 6401591
[TBL] [Abstract][Full Text] [Related]
3. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
Brock N; Stekar J
Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
[TBL] [Abstract][Full Text] [Related]
4. Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat.
Ormstad K; Uehara N
FEBS Lett; 1982 Dec; 150(2):354-8. PubMed ID: 6819161
[TBL] [Abstract][Full Text] [Related]
5. The fate of [14C]-mesna in the rat.
Shaw IC; Graham MI; Jones MS
Arzneimittelforschung; 1986 Mar; 36(3):487-9. PubMed ID: 3085684
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.
Ormstad K; Orrenius S; Låstbom T; Uehara N; Pohl J; Stekar J; Brock N
Cancer Res; 1983 Jan; 43(1):333-8. PubMed ID: 6401168
[TBL] [Abstract][Full Text] [Related]
7. Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection.
James CA; Rogers HJ
J Chromatogr; 1986 Oct; 382():394-8. PubMed ID: 3097045
[No Abstract] [Full Text] [Related]
8. Arginine 2-mercaptoethane sulfonate and sodium 2-mercaptoethane sulfonate: a comparative study of their effects upon tumour cells.
Magnolfi Zipoli G; D'Ancona S; Berti T
Drugs Exp Clin Res; 1988; 14(7):473-8. PubMed ID: 3149236
[TBL] [Abstract][Full Text] [Related]
9. Reduction of dimesna to mesna by the isolated perfused rat liver.
Goren MP; Hsu LC; Li JT
Cancer Res; 1998 Oct; 58(19):4358-62. PubMed ID: 9766664
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.
James CA; Mant TG; Rogers HJ
Br J Clin Pharmacol; 1987 May; 23(5):561-8. PubMed ID: 3109461
[TBL] [Abstract][Full Text] [Related]
11. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
Shaw IC; Weeks MS
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):933-5. PubMed ID: 3117563
[TBL] [Abstract][Full Text] [Related]
12. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Verschraagen M; Boven E; Torun E; Hausheer FH; Bast A; van der Vijgh WJ
Biochem Pharmacol; 2004 Aug; 68(3):493-502. PubMed ID: 15242815
[TBL] [Abstract][Full Text] [Related]
13. Bioavailability of orally administered mesna.
Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna.
Cutler MJ; Urquhart BL; Velenosi TJ; Meyer Zu Schwabedissen HE; Dresser GK; Leake BF; Tirona RG; Kim RB; Freeman DJ
J Clin Pharmacol; 2012 Apr; 52(4):530-42. PubMed ID: 21505084
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic and non-enzymatic mechanisms of dimesna metabolism.
Cutler MJ; Velenosi TJ; Bodalia A; House AA; Urquhart BL; Freeman DJ
Amino Acids; 2015 Mar; 47(3):511-23. PubMed ID: 25488427
[TBL] [Abstract][Full Text] [Related]
16. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
Brock N; Pohl J
IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
[TBL] [Abstract][Full Text] [Related]
17. Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna.
el-Yazigi A; Yusuf A; al-Rawithi S
Ther Drug Monit; 1995 Apr; 17(2):153-8. PubMed ID: 7624904
[TBL] [Abstract][Full Text] [Related]
18. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects.
Goren MP; Houle JM; Bush DA; Li JT; Newman CE; Brade WP
Clin Cancer Res; 1998 Oct; 4(10):2313-20. PubMed ID: 9796960
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of sodium 2-mercaptoethanesulfonate (MESNA) and its metabolite, disulfide form (DIMESNA), in volunteers after oral dosing: a comparison between MESNA and ARGIMESNA.
Pea F; Mazzo M; Miglioli PA; Casiglia E; Pessina A; Moretti V
Pharmacol Res; 1992; 25 Suppl 1():85-6. PubMed ID: 1508821
[No Abstract] [Full Text] [Related]
20. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.
Leeuwenkamp OR; Neijt JP; van der Vijgh WJ; Pinedo HM
Eur J Cancer; 1991; 27(10):1243-7. PubMed ID: 1835593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
